Peptide Compounding: Regulatory Status and the Gray Market

A compounding pharmacist filling a peptide prescription today is operating in one of the most unsettled corners of drug law. Most peptides patients request, including BPC-157 and thymosin beta-4 (TB-500), still sit outside the 503A Bulks List that governs lawful compounding for a patient. FDA has begun removing some peptides from Category 2, but removal does not place a substance on the Bulks List or make it compoundable. A pharmacy that treats removal as approval is compounding an unapproved drug, and every fill adds to the exposure.

Where Peptides Sit on the Bulks List

Section 503A of the Federal Food, Drug, and Cosmetic Act limits a compounding pharmacy to a defined universe of bulk drug substances: FDA-approved drugs, substances with a USP or NF monograph, or substances FDA has added to the 503A Bulks List after formal review. Most peptides satisfy none of the three (the 503A/503B distinction controls which entity may compound at all). FDA places substances it judges to raise significant safety risk into Category 2 of its bulk substance evaluation, a do-not-compound designation pending further review.

On April 15, 2026, FDA removed twelve peptides, including BPC-157, KPV, Semax, Epitalon, and thymosin beta-4 (TB-500), from Category 2 after their nominators withdrew the underlying safety-risk nominations, according to Frier Levitt's review of the FDA notice. The removal took effect within seven days and did not add any of the twelve to the Bulks List. The Pharmacy Compounding Advisory Committee met July 23 and 24, 2026 to evaluate several of these peptides for Bulks List inclusion. Until the committee recommends and FDA acts, compounding them for a patient has no lawful basis under Section 503A.

The Research-Use-Only Marketing Trap

Some suppliers sell peptide active pharmaceutical ingredient labeled research use only or not for human consumption, priced for patient dispensing rather than laboratory use. FDA does not evaluate the disclaimer on the label. It evaluates the marketing. In a February 26, 2025 warning letter to a peptide seller, FDA found that website claims describing semaglutide and tirzepatide products in clinical terms established the products' intended use as drugs for human use under 21 CFR 201.128, regardless of the research-use disclaimer. The letter cited violations of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FDCA for introducing misbranded and unapproved new drugs into interstate commerce.

Removal of a peptide from FDA's Category 2 safety list does not place it on the 503A Bulks List and does not make it lawful to compound.

A pharmacy sourcing peptide API from a research-use-only supplier carries this exposure twice. The API was never manufactured to pharmaceutical grade at an FDA-registered facility, and filling a patient-specific prescription with it is the conduct FDA's intended-use doctrine targets directly. Pharmaceutical-grade API for most of the twelve peptides removed from Category 2 is not yet available at commercial scale, according to Frier Levitt's review of the FDA action.

Board Scrutiny of Peptide Compounding Programs

State boards license compounding operations to work within Section 503A, and a substance's absence from the Bulks List gives a board grounds to open an inquiry independent of any FDA action. Board investigators reviewing a peptide program typically ask whether the substance appears on the Bulks List and whether the pharmacy can produce a certificate of analysis tracing the API to an FDA-registered facility. A pharmacy that cannot answer both faces board exposure even where FDA has not issued a warning letter on that peptide.

Board action moves on a different clock than federal enforcement. A license suspension can proceed administratively and reach the pharmacist-in-charge's license in every state where it is held, often before an FDA or DOJ matter resolves. A peptide program built around patient demand rather than current Bulks List status is exposed on the fastest-moving front first.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry related to peptide compounding. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to FDA or state board requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance represents compounding pharmacies navigating the peptide Bulks List gray market, from sourcing review through FDA warning letter response and state board defense. We evaluate a peptide program's current standing against the 503A Bulks List and Category 2 designations, trace API sourcing documentation, and respond directly to FDA and board inquiries on the pharmacy's behalf. If your pharmacy compounds peptides or is considering a peptide program, contact us today for a free consultation before an inquiry becomes an enforcement matter.